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Abstract
Background: The role of long non-coding RNAs (lncRNAs) in colorectal cancer (CRC) progression has not fully been
elucidated. This study was designed to report the identification of a novel lncRNA, lnc-GNAT1-1, and its functional
role in CRC progression.
Methods: lncRNA expression profile microarray was performed in three paired primary and liver metastatic tissues
of CRC, and a novel lncRNA, lnc-GNAT1-1, was identified to be a potential functional lncRNA. Quantitative real-time
PCR was used to detect its expression in CRC tissues, cell lines, and patients’ plasma, cell fractionation was used to
evaluate its subcellular location. lnc-GNAT1-1 was knockdown by siRNA or overexpressed by a lentivirus vector, then
in vitro an vivo experiments were performed to evaluate its biological role and the underlying mechanisms in CRC.
Results: Expression of lnc-GNAT1-1 was decreased in liver metastasis than the primary tumor, while the later one is
lower than the paired normal mucosa. Decreased lnc-GNAT1-1 expression was associated unfavorable clinicopathological
features and a poor prognosis of CRC patients. In multivariate analysis, lnc-GNAT1-1 was proved to be an independent
prognostic factor. In plasma, lnc-GNAT1-1 was significant decreased in CRC patients than healthy donors, and with the
TNM stages advanced, the plasma lnc-GNAT1-1 level decreased; Receiver operating characteristic curve (ROC curve)
showed that plasma lnc-GNAT1-1 had a moderate to well diagnostic efficiency for CRC. In vitro experiments
showed that knockdown of lnc-GNAT1-1 could inhibit the aggressive phenotypes of CRC cell lines. In vivo
study showed that overexpression of lnc-GNAT1-1 could suppress the liver metastasis of CRC cells. Finally, we
explored the underlying mechanism of the role lnc-GNAT1-1 plays in CRC, and found a positive correlation
between lnc-GNAT1-1 and Raf kinase inhibitor protein (RKIP) expression both in cells and in patients’ tissues.
We further found that lnc-GNAT1-1 could regulate the RKIP-NF-κB-Snail circuit in CRC.
Conclusions: We have demonstrated in this study that a novel lncRNA, lnc-GNAT1-1, is low expressed in
colorectal cancer tissues and plasma, and acts as a tumor suppressor through regulating RKIP-NF-κB-Snail
circuit.
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Background
Colorectal cancer is one of the leading cause of cancer-
related death around the world, and causes over a half
million deaths every year [1]. Despite considerable pro-
gresses have been made over the past decades in the
diagnostic approaches and therapeutic strategies, the
mortality of CRC is still high, especially for those who
suffers a distant metastasis. Thus, it is of great importance
for us to understand the biology, genetics and epigenetic
alterations in CRC, especially the detailed mechanisms
underlying distant metastasis, so as to improve the
prognosis of CRC patients.
Long non-coding RNAs (lncRNAs) are greater than
200 nucleotides without protein-coding potential. Recent
studies have shown that lncRNAs play a crucial role in
diverse biological processes, including alternative splicing,
nuclear import, imprinting, cell differentiation and RNA
decay [2, 3]. The dysregulation of lncRNAs have also been
shown to contribute to the initiation and progression of
many types of cancers, including colorectal cancer. Previous
studies have proved that long noncoding RNA H19 indi-
cates a poor prognosis of colorectal cancer and promotes
tumor growth by recruiting and binding to eIF4A3 [4];
LncRNA MALAT1 promotes tumor growth and metastasis
in colorectal cancer through binding to SFPQ and releasing
oncogene PTBP2 from SFPQ/PTBP2 complex [5]; Another
important lncRNA, HOTAIR, could regulate polycomb-
dependent chromatin modification and is associated with
poor prognosis in CRC.
To explore the role lncRNAs played in CRC liver metas-
tasis process, we performed lncRNA microarray using the
“LncRNA +mRNA Human Gene Expression Microarray
V4.0” (CapitalBio Technology, Beijing, China) according
to standard protocol in our unpublished study. Three
pairs of colorectal cancer and liver metastasis tissues were
tested. Among the differentially expressed lncRNAs, lnc-
GNAT1-1 was significantly low expressed in the liver
metastasis tissues than the primary tumor site. It is a
sense-overlapping long non-coding RNA located on
Chromosome 3 with a total of 11 transcripts, of which
four transcripts of lnc-GNAT1-1 were significantly
decreased in the metastatic tumor tissue, which indi-
cated that lnc-GNAT1-1 might have participated in the
liver metastasis processes of CRC cancer.
However, to the best of our knowledge, the biological
functions and the roles lnc-GNAT1-1 plays in cancer has
not been reported previously. Hence, in this study, we
sought to determine the expression and the biological
function of lnc-GNAT1-1 in CRC, especially its role in
liver metastasis. Expression levels of lnc-GNAT1-1 were
determined not only in the CRC primary tumor and liver
metastasis tissues, but also in the plasma of CRC patients,
and its correlations with clinicopathological parameters
were analyzed. We further studied the influence of
lnc-GNAT1-1 on the aggressive phenotypes of CRC
cell lines in vitro and in vivo. The regulatory role of
lnc-GNAT1-1 on RKIP were also explored to elucidate
the potential mechanisms. We have demonstrated that
a novel lncRNA, lnc-GNAT1-1, played a vital role in
the progression of CRC.
Methods
Patients and samples
Sixty-eight CRC patients who were diagnosed and under-
went surgery in Peking University People’s Hospital
between 2007 and 2015 were included in this study. Fresh
colorectal tumor tissues and matched normal colorectal
mucosa tissues were obtained from all the 68 patients.
Liver metastatic tumor tissues were obtained from 18 of
the 68 patients. The specimens were obtained and imme-
diately frozen in liquid nitrogen and stored at −80 °C until
RNA or protein extraction. Plasma samples from another
62 CRC patients were collected just before surgery
between 2014 and 2016. None of them received any anti-
neoplastic treatment. Plasma from 37 healthy donors with
matched age were collected as controls.
Cell lines and cell culture
The human CRC cell lines SW480, SW620, HT29, LoVo,
HCT116, and RKO cells were purchased from the
American Type Culture Collection (Manassas, VA, USA)
and subcultured and preserved by our lab. Cells were
maintained at 37 °C with 5% CO2 in Dulbecco’s Modi-
fied Essential Medium (DMEM) medium supplemented
with 10% fetal bovine serum (FBS, Gibco), 100 U/mL
penicillin (Sigma-Aldrich, St Louis, MO, USA), and
100 μg/mL streptomycin (Sigma-Aldrich).
RNA extraction and quantitative real-time PCR
Total RNA from cell lines and tissue samples was ex-
tracted using Trizol (Invitrogen) according to the manu-
facturer’s instructions. For the plasma, the total RNAs
were extracted using mirVanaTM PARISTM microRNA
extraction kit (ABI) according to the manufacturer’s
instructions. For lncRNA quantification, GAPDH was
used as internal control, and PrimeScriptTM RT Master
Mix (TAKARA) were used for reverse transcription and
real-time PCR. The primer sequences were as follows:
lnc-GNAT1-1 forward: 5′-ATGTGTCCCCAGGTTCCT
GTT-3′, lnc-GNAT1-1 reverse: 5′-CCCCTGAGGAC
TTGAGTAGC-3′; RKIP forward: 5′-GGAACGGGGA
GTGTACCAAG-3′, RKIP reverse: 5′-CCATCTGGTCG-
TAATCTTGAAGG-3′. GAPDH forward: 5′- GCAA
GAGCACAAGAGGAAGA-3′, GAPDH reverse: 5′-AC
TGTGAGGAGGGGAGATTC-3′. All reactions were
performed in triplicate. The fold change for each gene
relative to the control group was calculated using the 2
−ΔΔCt method.
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Western blot analysis
Total protein extracts were separated by Trisglycine poly-
acrylamide gels and transferred to polyvinylidene fluoride
membranes (General Electric Healthcare, Buckinghamshire,
UK). Membranes were incubated with primary antibodies
followed by horseradish peroxidase-labeled secondary
antibody. GAPDH was used as a loading control.
The antibodies used in the experiments are shown in
Additional file 1: Table S1.
Subcellular fractionation
The separation of nuclear and cytosolic fractions was
carried out using the PARIS Kit (Life Technologies)
according to the manufacturer’s instructions. For quanti-
fication PCR, GAPDH and U6 were used as used as
fractionation indicators. Primer sequence for U6 was:
Forward: 5′- CTCGCTTCGGCAGCACA-3′.
Cell transfection
For in vitro assays, to interfere the expression of lnc-
GNAT1-1, siRNA interference sequences targeting Lnc-
GNAT1-1 were designed and synthetized (GenePharma,
Shanghai, China), and a final concentration of 50nM
were used for transient transfection; to overexpress lnc-
GNAT1-1, full-length human lnc-GNAT1-1 cDNA was
cloned into the pcDNA3.1 expression vector (GenePharma,
Shanghai, China). Lipofectamine 3000 (Invitrogen, Carlsbad,
CA, USA) was used for transfection according to manufac-
turer’s instructions.
For in vivo studies, lnc-GNAT1-1 overexpression
cell line was used. The lnc-GNAT1-1 gene was
cloned in to a lentivirus vector LV-GFP-Puro, and
RKO cells were used for infection. Stable transfection
cells were established by puromycin antibiotic selec-
tion applied for 3 days, with a concentration of 5ug/
ml. The lnc-GNAT1-1 overexpression cells and con-
trol cells were named RKO-LV-lnc-GNAT1-1 and
RKO-LV-NC, respectively.
Cell proliferation assays and flow cytometry analysis
Cell proliferation assay was performed with Cell Counting
Kit-8 (CCK8) according to the manufacturer’s protocol,
and detected at 0, 24, 48, 72 and 96 h. Cells in each group
were tested for 5 replicates.
For colony formation assay, transfected cells were
seeded into each well of a 6-well plate on day 0 then
incubated for another 12d. Then, the wells were fixed
with 4% paraformaldehyde, and stained with 0.1% crystal
violet. The form colonies were counted and analyzed by
Image J software.
Cells were cultured in 6-wells plate until the cell density
reached more than 95% confluence. Then, a vertical
wound was scratched using a 100ul microtip. The cells
were washed with phosphate-buffered saline (PBS) twice
to remove the cell debris. Images were captured at 0 and
24 h or 36 h to assess wound closure.
For cell cycle analysis, cells were stained with propi-
dium iodide (PI) solution (BD Cycletest™ Plus DNA Kit)
and were analyzed by a fluorescence-activated cell sorter
(FACS) 48 h after transfection. For apoptosis analysis,
48 h after transfection, cells were stained with BD FITC
Annexin V Apoptosis Detection Kit I followed by FACS
analysis according to the manufacturer’s protocol.
Cell migration and invasion assays
Cell invasion assay was performed using Corning
Polycarbonate Membrane Insertin transwell chamber
(Product #3422, Corning Costar Corp, Cambridge,
MA, USA). After transfection for 24 h, cells (1 × 105)
in serum-free media were placed into the upper
chamber to do migration assays (without Martrigel)
and invasion assays (with Martrigel, Sigma). Media
containing 20% FBS was placed in the lower cham-
ber as a chemoattractant. After 48 h incubation, the
non-invading cells were removed with cotton swabs.
Migrated or invasive cells at the bottom of the
membrane were stained with methanol 0.1% crystal
violet and images were captured under the micro-
scope. The number of the cells were counted by
Image J software.
Liver metastasis model in nude mice
Stably transfected cells were washed twice and resuspended
in 1 ×Hank’s buffer at a concentration of 2 × 107 cells/mL.
A 50 μL cell suspension was then injected into the inferior
pole of the spleen of Balb/c athymic mice under anesthesia.
4 mice were included in each group. Mice were sacrificed
7 weeks after operation, and the spleens and livers were
surgically excised. The number and size of formed tumors
in the spleen and liver were documented. Moreover, the
metastatic lesions were determined by hematoxylin and
eosin (HE) staining.
Statistical analysis
SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) was
used to perform the statistical analysis. Data were pre-
sented as mean ± SD from at least three separate experi-
ments. Comparison between groups was made using the
Student’s unpaired t-test (2-tailed). Paired qPCR relative
expression results were compared with Wilcoxon Signed
Ranks test. The Chi-squared test (χ2 test) was used to
evaluate the relationship between the clinicopathological
features and lnc-GNAT1-1 expression. Kaplan–Meier
analysis and Cox regression analysis was used for sur-
vival analysis. For all, P values of <0.05 were considered
statistically significant.
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Results
lnc-GNAT1-1 is low expressed in CRC tissues
As mentioned above, we previously conducted lncRNA
microarray and explored the global expression profiles
of lncRNAs in colorectal cancer primary tissues and liver
metastatic tissues. Among the 98 differentially expressed
lncRNAs transcripts, we noticed that four transcripts of
lncRNA lnc-GNAT1-1 (lnc-GNAT1-1:9, 11, 10, 1) were
remarkably higher in primary CRC tissues than the liver
metastatic tissues, with an average fold change of 42.81.
To verify this result, we determinate the expression of
lnc-GNAT1-1 in 18 paired CRC primary and liver metas-
tasis tissues. Results showed that lnc-GNAT1-1 was
significantly decreased in liver metastatic tissues com-
pared with primary tumor (Fig. 1a). We further detected
lnc-GNAT1-1 expression in another 68 CRC tissues and
matched normal mucosa. We found that expression of
lnc-GNAT1-1 was significantly up-regulated in tumor
tissues. Among the 68 CRC patients, 69.12% (47/68)
showed decreased expression of lnc-GNAT1-1 in tumor
tissues compared with paired normal mucosa (P < 0.001,
Fig. 1b). The above data were in agreement with the
microarray results and indicated that lnc-GNAT1-1 might
be involved in the occurrence and progression of CRC.
Decreased expression of lnc-GNAT1-1 predicts a poor
prognosis of CRC patients
Based on the real-time PCR results of the tissues,
we divided all the 68 patients into high expression
group and low expression group according to the
median expression level (Fig. 1c). As shown in
Table 1, the lnc-GNAT1-1 level in cancer tissues was
associated with lymphovascular invasion (p = 0.012),
depth of tumor invasion (p = 0.028), distant metasta-
sis (p = 0.022), and tumor stage (p = 0.027). While no
significant correlation was detected with other clini-
copathological features, such as age, gender, tumor
size, and differentiation.
Fig. 1 Expression of lnc-GNAT1-1 in CRC tissues and its association with OS. a Expression of lnc-GNAT1-1 was decreased in liver metastatic tissues
than the primary tumor tissues, with an average fold change of 2.22 (P = 0.004). b lnc-GNAT1-1 expression was significantly deregulated in tumor
tissues compared with the paired adjacent normal tissues, with an average fold change of 2.04 (P < 0.001). c All the 68 CRC patients were divided
into high lnc-GNAT1-1 group (n = 34) and low lnc-GNAT1-1 group (n = 34) according to the median expression level. d Kaplan-Meier analysis
showed that low expression of lnc-GNAT1-1 was associated with a poor overall survival of CRC patients (P = 0.001)
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The follow-up time of all patients was from March
2007 to November 2015, with a median survival time of
62.50 months. Kaplan-Meier analysis with log-rank test
was performed to evaluate the influence of lnc-GNAT1-
1 expression on the overall survival (OS) of CRC pa-
tients. The patients in the high lnc-GNAT1-1 expression
group has a significant longer OS than those in the low
expression group (55.75 vs. 68.59 months, p = 0.001). In
univariate Cox regression analysis of OS, lnc-GNAT1-1
expression, lymphovascular invasion, depth of tumor
invasion, lymph node metastasis, distant metastasis and
tumor stage were identified as prognostic indicators,
while in multivariate Cox regression analysis, only lnc-
GNAT1-1 expression (p = 0.046), lymph node metastasis
(p = 0.031) and distant metastasis (p = 0.044) could be
served as independent prognostic factors (Table 2).
Plasma lnc-GNAT1-1 is decreased in CRC patients
As lncRNAs have the potential to be applied as non-
invasive biomarkers for cancer detection, we next de-
tected the level of circulating lnc-GNAT1-1 in CRC
patients. Plasma lnc-GNAT1-1 was detected in 88.71%
(55/62) CRC patients and 94.59% (35/37) healthy con-
trols. The plasma level of lnc-GNAT1-1 was signifi-
cantly higher in healthy controls than in CRC patients
(P < 0.001), with an average fold change of 2.25. Espe-
cially, after stratification by TNM stages, plasma lnc-
GNAT1-1 level showed a decreased trend with the
stages advanced. In our analysis, stage I and stage II
cases were grouped together because of limited Stage I
cases. The mean relative expression of plasma lnc-
GNAT1-1 level in stage I+ II, stage III and stage IV
patients were 0.56, 0.25, 0.10, respectively (Fig. 2a),
stage III and stage IV patients had significant lower
plasma lnc-GNAT1-1 levels than stage I+ II patients.
Next, we examined the diagnostic efficiency of lnc-
GNAT1-1 in CRC using the ROC curve. As shown in
Fig. 2b, the area under the curve (AUC) of the ROC
Table 1 Association of lncG expression and clinicopathological
features in CRC patients
Clinicopathological
features
lncG expression P value
Low (%) High (%)
Gender
Male 23(56.10) 18(43.90) 0.215
Female 11(40.74) 16(59.26)
Age
< 60 8(38.10) 13(61.90) 0.189
≥ 60 26(55.32) 21(44.68)
Tumor size (cm)
< 4 14(40.00) 21(60.00) 0.089
≥ 4 20(60.61) 13(39.39)
Lymphovascular invasion
Absent 21(41.17) 30(58.82) 0.012
Present 13(76.47) 4(23.53)
Differentiation
Well-moderate 24(53.33) 21(46.67) 0.442
Poor 10(43.48) 13(56.52)
Depth of invasion
T1 + T2 11(35.48) 20(64.52) 0.028
T3 + T4 23(62.16) 14(37.84)
Lymph node metastasis
N0 11(37.93) 18(62.07) 0.086
N1-2 23(58.97) 16(41.03)
distant metastasis
M0 22(42.31) 30(57.69) 0.022
M1 12(75.00) 4(25.00)
TNM stage
I + II 10(34.48) 19(65.52) 0.027
III + IV 24(61.54) 15(38.46)
Table 2 Cox proportional hazard regression model analysis
Variables Univariate Cox’s regression analysis Multivariate Cox’s regression analysis
Relative risk 95% CI P value Relative risk 95% CI P value
Lymphovascular invasion
present versus absent 3.503 1.692-7.251 0.001
lncG expression
high versus low 0.324 0.160-0.656 0.002 0.462 0.216-0.988 0.046
T stage
T3 + T4 versus T1 + T2 2.633 1.311-5.290 0.007
N stage
N1 + N2 versus N0 3.470 1.669-7.213 0.001 2.412 1.083-5.375 0.031
Metastasis
Yes versus No 5.024 2.436-10.363 <0.001 2.394 1.025-5.596 0.044
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curve was 0.720, which indicated that serum lnc-
GNAT1-1 level possessed a moderate to strong diag-
nostic efficiency for CRC patients.
Expression and subcellular localization of lnc-GNAT1-1 in
CRC cell lines
Next, the expression of lnc-GNAT1-1 was determined in
6 CRC cell lines. As shown in Fig. 2c, lnc-GNAT1-1 had
the lowest expression in the poorly differentiated and
highly aggressive RKO cells; it had the highest expres-
sion in the SW480 cell line, while in its metastatic
derivation cell line SW620, the expression level was
decreased.
Then, lnc-GNAT1-1 was analyzed for nucleic-
cytoplasmic compartmentalization by subcellular frac-
tionation of SW480 and LoVo cells (Fig. 2d). We
observed a considerable enrichment of lnc-GNAT1-1
expression in the nucleus versus the cytoplasm, which
suggested that lnc-GNAT1-1 was mainly localized in
the nucleus and maybe exerted its functions at the
transcriptional level or through interacting with the
nuclear proteins (Fig. 2e).
Influence of lnc-GNAT1-1 on the malignant phenotypes of
CRC cells
Then, to elucidate the role of lnc-GNAT1-1 in tumor pro-
gression, we down-regulated the lnc-GNAT1-1 expression
using siRNA or a negative control in SW480 cells. The
inhibitory rate (lnc-GNAT1-1 siRNA vs. negative control
siRNA) was 88.0% (Fig. 3a). In vitro experiments in SW480
cells showed that inhibition of lnc-GNAT1-1 promoted cell
growth in CCK8 cell proliferation assay (Fig. 3b) and
increased colony formation ability (Fig. 3c). In flow
cytometry analysis, the si-lnc-GNAT1-1 SW480 cells
exhibited decreased apoptosis rate (10.16% vs. 17.71%,
P < 0.001) and accelerated cell cycle (G0/G1%: 45.50%
vs. 50.65%, P < 0.001) when compared with si-NC cells
(Fig. 3d,e). Wound healing ability was also enhanced in
the si-lnc-GNAT1-1 cells (Fig. 3f ). Finally, in the
experiment of transwell migration and invasion assays,
inhibition of lnc-GNAT1-1 could significantly enhance
the migration and invasion abilities of SW480 cells
(Fig. 3g).
To verify the above results, we further overexpressed lnc-
GNAT1-1 in LoVo cells using the pcDNA3.1 plasmid
Fig. 2 Expression of lnc-GNAT1-1 in CRC patients’ plasma, as well as its expression in CRC cell lines and its subcellular location. a Expression of
lnc-GNAT1-1 was decreased in plasma of CRC patients than the normal controls (relative expression levels, 0.33 vs 0.72, P < 0.001). b Plasma lnc-
GNAT1-1 levels were decreased with the TNM stages advanced. Its relative expression levels in stage I+ II, stage III and stage IV patients were 0.56,
0.25, 0.10, respectively. c ROC curve analysis of lnc-GNAT1-1 for discriminative ability between CRC cases and normal controls, with an AUC of
0.702. d Relative expression of lnc-GNAT1-1 in 6 CRC cell lines, with the highest in SW480, and the lowest in RKO cells. e Subcellular fractionation
for lnc-GNAT1-1 in SW480 and LoVo cells, U6 and GAPDH were set as controls. Lnc-GNAT1-1 has a predominate localization in the nucleus.
*P < 0.05, ***P < 0.001
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vector. Our results showed that when lnc-GNAT1-1 was
overexpressed, the proliferation, colony formation and
wound healing abilities of LoVo cells were inhibited
(Fig. 4b,c, and f). Flow cytometry analysis also showed an
arrested cell cycle (G0/G1%: 46.54% vs. 38.92%, P < 0.001,
Fig. 4d), as well as a increased cell apoptosis rate (13.71% vs.
6.96%, P < 0.001, Fig. 4e) when compared with control cells.
In transwell migration and invasion assays, overexpression
of lnc-GNAT1-1 attenuated the migratory and invasive abil-
ities of LoVo cells (Fig. 4g). The above in vitro experiments
performed in the two CRC cell lines suggested that overex-
pression of lnc-GNAT1-1 may suppress the malignant phe-
notypes of CRC cell lines, and inhibition of its expression
will bring about more aggressive phenotypes of CRC cells,
which was in correspondence with the clinical findings.
Lnc-GNAT1-1 suppressed the distant metastasis of CRC
cell line in vivo
Next, we evaluated the effect of lnc-GNAT1-1 on CRC liver
metastasis process in vivo through injecting lnc-GNAT1-1
overexpression cells (RKO-LV-lnc-GNAT1-1) as well as
negative control cells (RKO-LV-NC) into spleens of female
nude mice. Seven weeks after injection, the mice were
sacrificed, and the formed metastatic tumors on the liver
were examined. In LV-lnc-GNAT1-1 group, all four mice
formed primary tumors in spleens, as well as metastatic
tumors in livers. In contrast, in the control group, only two
mice formed tumors in the spleen, and liver metastasis was
detected only in one of the above two mice (Fig. 5). The
results suggest that overexpression of lnc-GNAT1-1 could
significantly suppress liver metastasis of CRC cells.
Fig. 3 Suppression of lnc-GNAT1-1 promoted proliferation, colony formation, cell motility, migration and invasion of SW480 cells. a The efficiency of
lnc-GNAT1-1 knockdown was verified by real-time PCR, with the interference efficiency of around 90%. b Cell proliferation was determined by CCK8
assay, in which si-lnc-GNAT1-1 cells had a significant promoted proliferation rate than the control cells during a period of 96 h. c Plate colony formation
assay showed increased colony formation ability of si-lnc-GNAT1-1 cells than the control cells (78.67 ± 4.51 vs. 157.30 ± 10.07, P < 0.001). d Cell cycle
analysis showed that inhibition of lnc-GNAT1-1 could accelerate the cell cycle when compared with the control cells (G0/G1%: 45.50 ± 0.53% vs. 50.65
± 0.31%, P < 0.001). e Flow cytometry analysis on apoptosis of cells showed that knockdown of lnc-GNAT1-1 decreased the number of apoptotic cells
than control cells (10.17 ± 0.27%, 17.71 ± 0.26%, respectively, P < 0.001). f Wound healing assay during a period of 24 h showed an increased wound
healing capacity of si-lnc-GNAT1-1 cells (Magnification × 100). g Transwell migration (upper) and invasion (lower) assays showed that
enhanced migration (551.67 ± 21.83 vs. 208.67 ± 14.57, P < 0.001) and invasion (664.67 ± 31.70 vs. 246.00 ± 11.37, P < 0.001) capacities of
SW480 cells following suppression of lnc-GNAT1-1 (Magnification × 100)
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Lnc-GNAT1-1 regulates RKIP-NF-κB-Snail circuit in CRC
We further explored the underlying mechanism of the
role lnc-GNAT1-1 played in CRC cancer biology. Based
on our microarray data, the mRNA and lncRNA co-
expression analysis was performed, and significant
correlation was defined as correlation > 0.99 or correl-
ation < −0.99, and P value <0.05. A total of 22 genes
were identified to be significantly co-expressed with lnc-
GNAT1-1, of which, RKIP gene has the highest correlation
coefficient (0.9977). Previous studies have shown that RKIP
played a tumor suppressor role in cancers [6–8], including
CRC [9, 10], through participating in a RKIP-NF-κB-Snail
circuitry [11–13]. So in the present study, we decided to
investigate whether lnc-GNAT1-1 could regulate the ex-
pression of RKIP, and further affect the RKIP -NF-κB-Snail
circuitry to play its tumor suppressor role in CRC. We
knocked down and overexpressed lnc-GNAT1-1 in SW480
cells and LoVo cells, respectively. Then we detected the
mRNA and protein expression levels of RKIP, with results
showed that RKIP expression was decreased following lnc-
GNAT1-1 knockdown, and vice versa (Fig. 6a and b). We
further detected the expressions of NF-κB and Snail
proteins in the above cells, with results showed that when
lnc-GNAT1-1 was knocked down, expressions of NF-κB
and Snail increased, while when lnc-GNAT1-1 was overex-
pressed, expression of the two proteins decreased (Fig. 6b).
sThen, correlation between expression of lnc-GNAT1-1
and mRNA level of RKIP were assessed in the above 68
CRC cancer tissues, and Pearson correlation analysis
showed a significant positive correlation between them
Fig. 4 Overexpression of lnc-GNAT1-1 promoted proliferation, colony formation, cell motility, migration and invasion of LoVo cells. a LoVo cells were
transiently transfected with lnc-GNAT1-1 expression plasmid, and the efficiency of lnc-GNAT1-1 overexpression was verified by real-time PCR, with the
fold change of nearly 8 times. b CCK8 assay showed that lnc-GNAT1-1 overexpressed cells exhibited a remarkably decreased proliferation rate. c Colony
formation assay showed that overexpression of lnc-GNAT1-1 decreased the formed colonies of LoVo cells. d & e Flow cytometry analysis showed that
compared with control cells, overexpression of lnc-GNAT1-1 could induce cell apoptosis (13.71 ± 0.12%, 6.96 ± 0.12%, respectively, P < 0.001) and hinder
cell cycle (G0/G1%: 46.54 ± 0.29% vs. 38.92 ± 0.28%, respectively, P < 0.001). f Wound healing assay showed that overexpression of lnc-GNAT1-1 could
inhibit the mobility of LoVo cell (Magnification × 100). g Transwell migration (upper) and invasion (lower) assays showed that overexpression of
lnc-GNAT1-1 could decrease the migration and invasion abilities of LoVo cells (Magnification × 100)
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(R = 0.645, P < 0.001, Fig. 6c). Furthermore, rescue ex-
periments was performed to see whether the tumor
suppressive effect of lnc-GNAT1-1 could be attenuated
through reintroduction of RKIP into the cells. CCK8
assay (C. 6d) and transwell migration assay (C. 6e) were
performed, and the results had shown a significant
rescue effect of RKIP on proliferation and metastasis of
SW480 cells with lnc-GNAT1-1 knockdown.
Discussion
LncRNAs have attracted immense research interests from
researchers worldwide in recent years. Based upon our
previous lncRNA microarray data, we identified a novel
lncRNA, lnc-GNAT1-1, which was significantly low
expressed in liver metastatic tissues than the primary CRC
tumors. Therefore, we explored the role of lnc-GNAT1-1
in CRC in this study. We found that decreased expression
of lnc-GNAT1-1 in cancer tissues was associated with
lymphovascular invasion, depth of tumor invasion, distant
metastasis, tumor stage, as well as OS of the patients; it
could be served as an independent prognostic factor for
CRC patients. What’s more, our in vitro and in vivo exper-
iments showed that inhibition of lnc-GNAT1-1 could
promote the malignant phenotypes of CRC cells, while
overexpression of lnc-GNAT1-1 generate an opposite
effect. Thus, our data confirmed the hypothesis that as a
novel lncRNA, lnc-GNAT1-1 exerts tumor suppressive
activity to inhibit cell proliferation and metastasis in
Fig. 5 Overexpression of lnc-GNAT1-1 suppressed liver metastasis of CRC cells in vivo. a Pictures of the excised livers and spleens of BALB/c nude
mice. The tumor formation in spleens and metastasis in livers were apparently suppressed in lnc-GNAT1-1 overexpression group (4 in spleen and
4 in liver) than the control group (2 in spleen and only 1 in liver). b Representative photos of haematoxylin and eosin (HE) staining sections
showed livers and spleens with or without tumors (Magnification × 200)
Fig. 6 Lnc-GNAT1-1 regulates RKIP-NF-κB-Snail circuit in CRC. a Expression of RKIP was decreased or increased following knockdown or overexpression of
lnc-GNAT1-1 at the mRNA level. b Protein expression levels of RKIP, NF-Kb and Snail were determined in SW480 and LoVo cells following lnc-GNAT1-1
knockdown or overexpression. c A positive correlation between expression of lnc-GNAT1-1 and RKIP was detected in 68 CRC patients’ cancerous tissues,
with R2 = 0.416, P < 0.001. d Rescue experiment showed that reintroduction of RKIP could attenuate the influence of lnc-GNAT1-1
knockdown on proliferation and (e) migration in SW480 cells (Magnification × 100)
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colorectal cancer. The underlying molecular mechanisms
might be attributed to its regulation on the RKIP -NF-κB-
Snail circuit, which had been demonstrated in this study.
Especially, as one of the most investigated transcription
factors, NF-κB has been proved to regulate multiple cellu-
lar processes in cancer, including proliferation, invasion,
metastasis, angiogenesis, and chemoresistance [14, 15].
The role lncRNA played in biology of CRC has been
studied in recent years, while studies that focused on
CRC liver metastasis were limited. To our knowledge,
only one previous study was designed to explore the
lncRNAs related with liver metastasis of CRC. Ye and
colleagues [16] performed lncRNA arrays to screen for
differentially expressed lncRNAs in CRC tissues with
synchronous, metachronous, or nonliver metastasis. In
their study, 40 differentially expressed lncRNAs that
were potentially related to CRC liver metastasis were
selected and examined, of which three novel target
lncRNAs, termed lncRNA-CLMAT1-3, were verified.
The difference between their study and ours is that they
compared the differentially expressed lncRNAs in
primary tumors, with or without liver metastasis, while
our study compared the metastatic tumors with the
primary tumors.
Another important finding of this study is that lnc-
GNAT1-1 is decreased in plasma of CRC patients than in
healthy controls, with an AUC of 0.720 in the ROC ana-
lysis, which indicates that lnc-GNAT1-1 has a moderate
to well efficiency for the diagnosis of CRC. Recently, many
studies have focused on lncRNAs as potential tumor
markers for cancer diagnosis and prognosis for their
stability and non-invasiveness. Zhou et al. evaluated the
potential of 8 lncRNAs as diagnostic markers for gastric
cancer, and finally confirmed that plasma H19 could serve
as potential diagnostic biomarker for gastric cancer, in
particular for early stage patients [17]. In addition, other
potential plasma lncRNA markers have been identified,
for instance, HULC for hepatocellular carcinoma [18],
lncRNA-UCA1 for lung cancer [19], POU3F3 for esopha-
geal squamous cell carcinoma [20]. What’s more, in our
study we also found that plasma lnc-GNAT1-1 was related
with patients’ TNM stages, that was, with the tumor
stages advanced, the plasma lnc-GNAT1-1 level decreased.
This suggest that monitoring the plasma lnc-GNAT1-1
level might be help to identify those patients who suffer an
advanced stage of disease or distant metastasis early, which
will be beneficial for prognosis of the patients.
Although the detailed mechanisms that lncRNAs par-
ticipate in cancer biology have yet to be elucidated,
current studies have shown that the gene regulation role
lncRNAs played is mainly through its interacting with
proteins, especially nuclear proteins, because lncRNAs
(including lnc-GNAT1-1), were predominantly located at
the cell nucleus. Previous studies have shown a variety of
interactions between lncRNAs and proteins, for instance,
LOC389641 with E-cadherin [21], SNHG5 with MTA2
[22], and CASC11 with hnRNP-K [23]. In this study, a
significant positive expression correlation between lnc-
GNAT1-1 and RKIP was detected. RKIP has been
reported to be a tumor suppressors in a variety of cancer
types, including colorectal cancer [9, 10, 24], gastric can-
cer [25, 26], esophageal cancer [27], breast cancer [28],
etc., and the mechanisms were mainly attributed to its
involvement in the RKIP -NF-κB-Snail circuit in previous
reports [13, 29, 30]. In this study, we found a positive
correlation between expression of lnc-GNAT1-1 and
RKIP, both in cells level and in patients’ tissues. What’s
more important, after RKIP was overexpressed, the
enhancement of down-regulated lnc-GNAT1-1 on cell
proliferation and invasion was hindered, which indicated
that the tumor suppressive effect of lnc-GNAT1-1 might
be mediated through RKIP. While the detailed regulatory
effect between lnc-GNAT1-1 and RKIP was unknown.
According to previous reports, RKIP protein was located
primarily in the cytoplasm, still it could be found in the
nucleus, as indicated by several references [31–33]. So it
raises the question about the location that lnc-GNAT1-1
interacts with RKIP, directly in the nucleus or indirectly
through some intermediate proteins, such as transcription
factors. Actually we present in this study that the other
two proteins besides RKIP in the RKIP -NF-κB-Snail
circuit could also be regulated by lnc-GNAT1-1. Further
work is necessary to determine the details of the inter-
action between lnc-GNAT1-1 and the RKIP -NF-κB-Snail
circuit.
Conclusion
In conclusion, we have identified a novel lncRNA, lnc-
GNAT1-1, which is decreased in CRC tissues and plasma
and associated with higher overall survival of CRC
patients. It could inhibit the aggressive phenotypes of
CRC cells both in vitro and in vivo. We also showed in
this study that lnc-GNAT1-1 could regulate the RKIP
-NF-κB-Snail circuit in CRC cells. Our results have
provide a new therapeutic target for CRC treatment.
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